ω-酞酰亚胺己酸 | 4443-26-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: ω-酞酰亚胺己酸
• 中文别名: 6-(1,3-二氧代-1,3-二氢-异吲哚-2-基)-己酸
• 英文名称: 6-phthalimidohexanoic acid
• 英文别名: 6-(1,3-dioxoisoindolin-2-yl)hexanoic acid；6-(1,3-dioxo-1,3-dihydroisoindol-2-yl)hexanoic acid；Phthalimidocapronic acid；6-(1,3-dioxoisoindol-2-yl)hexanoic acid
• CAS: 4443-26-9
• 化学式: C₁₄H₁₅NO₄
• mdl: MFCD00233499
• 分子量: 261.277
• InChiKey: QJDSLDWVMCWWCO-UHFFFAOYSA-N

物化性质

• 熔点：
  107 °C(Solv: water (7732-18-5))
• 沸点：
  239-240 °C(Press: 3 Torr)
• 密度：
  1.301±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.357
• 拓扑面积：
  74.7
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2925190090
• 危险性防范说明：
  P261,P264,P271,P280,P302+P352,P304+P340,P305+P351+P338,P312,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H315,H319,H335,H303
• 储存条件：
  -20°C，干燥且密封保存。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 6-(1,3-Dioxoisoindol-2-yl)hexanoic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 6-(1,3-Dioxoisoindol-2-yl)hexanoic acid
CAS number: 4443-26-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C14H15NO4
Molecular weight: 261.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

6-N-Phthalimidohexanoic acid（化合物FH）是一种半抗原，其间隔臂末端含有羧基，能够与蛋白质的游离胺基反应。这种化合物可以与载体蛋白结合，用于抗原设计。

反应信息

• 作为反应物：
  描述：

  ω-酞酰亚胺己酸 在 1,4-二氧六环 、 氯化亚砜 、 水 、 magnesium oxide 作用下， 生成 6-phthalimido-hexanoic acid anilide
  参考文献：
  名称：

  van der Want; Staverman, Recueil des Travaux Chimiques des Pays-Bas, 1952, vol. 71, p. 379,383

  摘要：

  DOI：
• 作为产物：
  描述：

  1,5-二氯戊烷 在 乙醇 、 硫酸 作用下， 生成 ω-酞酰亚胺己酸
  参考文献：
  名称：

  Albert, Chemische Berichte, 1909, vol. 42, p. 549

  摘要：

  DOI：
• 作为试剂：
  描述：

  1,1-二苯乙烯 在 sodium nitrate 、 sodium dihydrogenphosphate 、 sodium persulfate 、 ω-酞酰亚胺己酸 、 4,7-二苯基-1,10-菲罗啉 、 silver nitrate 作用下， 以 水 、 1,2-二氯乙烷 为溶剂， 生成
  参考文献：
  名称：

  银催化脂肪族羧酸的脱羧硝氧基化

  摘要：

  在这里，我们通过基于自由基的方法提出了银催化脱羧硝氧基化。该反应原型的底物范围延伸至未活化的伯羧酸和仲羧酸。该方案为合成前所未有的有机硝酸盐家族提供了一种实用方法，并表现出广泛的官能团兼容性。初步机理研究表明，高价硝酸银 (II) 络合物是一种多功能的 NO 3资源库，可以轻松形成 C-O 键。

  DOI：

  10.1021/acs.orglett.4c02180

文献信息

• Synthesis of 5-amino-2-aminoalkyl-1,3-oxazol-4-ylphosphonic acid derivatives and their use in the preparation of phosphorylated peptidomimetics
  作者：Kostyantyn M. Kondratyuk、Olena I. Lukashuk、Aleksandr V. Golovchenko、Igor V. Komarov、Volodymyr S. Brovarets、Valery P. Kukhar

  DOI：10.1016/j.tet.2013.05.017

  日期：2013.7

  Starting from phthalimidoalkanoylamines 1 (amino-protected derivatives of glycine, β-alanine, γ-amino butyric, δ-amino valeric, and ε-amino caproic acids), a facile synthetic method has been developed to obtain diethyl 5-alkyl(dialkyl)amino-2-aminoalkyl-1,3-oxazol-4-ylphosphonates 7, which have been further used in the preparation of phosphorylated peptidomimetics 10 and 12.

  从邻苯二甲酰亚胺基链烷胺1（甘氨酸，β-丙氨酸，γ-氨基丁酸，δ-氨基戊酸和ε-氨基己酸的氨基保护衍生物）开始，已经开发了一种简便的合成方法以获得5-乙基二烷基二乙基氨基-2-氨基烷基-1,3-恶唑-4-基膦酸酯7，已进一步用于制备磷酸化拟肽10和12。
• ω-Phthalimidoalkyl Aryl Ureas as Potent and Selective Inhibitors of Cholesterol Esterase
  作者：Florian M. Dato、Miriam Sheikh、Rocky Z. Uhl、Alexandra W. Schüller、Michaela Steinkrüger、Peter Koch、Jörg-Martin Neudörfl、Michael Gütschow、Bernd Goldfuss、Markus Pietsch

  DOI：10.1002/cmdc.201800388

  日期：2018.9.6

  with an attached 3,5‐bis(trifluoromethyl)phenyl group and the aromatic character of the ω‐phthalimide residue were most important for inhibitory activity. In addition, an alkyl chain composed of three or four methylene groups, connecting the urea and phthalimide moieties, was found to be an optimal spacer for inhibitors. The so‐optimized compounds 2 [1‐(3,5‐bis(trifluoromethyl)phenyl)‐3‐(3‐(1,3‐di

  胆固醇酯酶（CEase）是一种丝氨酸水解酶，被认为与动脉粥样硬化有关，因此与冠心病有关，被认为是抑制剂发展的目标。在一个小的ω-邻苯二甲酰亚胺基烷基芳基尿素文库的结构-活性关系研究中，我们用新的荧光测定法研究了重组人和鼠类CEase。带有3,5-双（三氟甲基）苯基的尿素基序和ω-邻苯二甲酰亚胺残基的芳香特性对于抑制活性最重要。另外，发现由三个或四个连接尿素和邻苯二甲酰亚胺部分的亚甲基组成的烷基链是抑制剂的最佳间隔基。如此优化的化合物2 [1-（3,5-双（三氟甲基）苯基）-3-（3-（1,3-二氧代异吲哚啉-2-基）丙基）脲]和21[1-（3,5-双（三氟甲基）苯基）-3-（4-（1,3- dioxoisoindolin -2-基）丁基）脲]显示解离常数（ķ我的1-19μ）米上的两种CEase并显示出竞争性抑制作用（对人类酶而言为2种，对鼠类酶而言为21种）或非竞争性抑制方式。ω-邻苯二甲
• Live-Cell Protein Modification by Boronate-Assisted Hydroxamic Acid Catalysis
  作者：Christopher Adamson、Hidetoshi Kajino、Shigehiro A. Kawashima、Kenzo Yamatsugu、Motomu Kanai

  DOI：10.1021/jacs.1c07060

  日期：2021.9.22

  Selective methods for introducing protein post-translational modifications (PTMs) within living cells have proven valuable for interrogating their biological function. In contrast to enzymatic methods, abiotic catalysis should offer access to diverse and new-to-nature PTMs. Herein, we report the boronate-assisted hydroxamic acid (BAHA) catalyst system, which comprises a protein ligand, a hydroxamic

  在活细胞中引入蛋白质翻译后修饰 (PTM) 的选择性方法已被证明对研究其生物学功能很有价值。与酶法相比，非生物催化应该提供对各种新自然 PTM 的访问。在此，我们报道了硼酸盐辅助的异羟肟酸（BAHA）催化剂体系，该体系由蛋白质配体、异羟肟酸路易斯碱和二醇部分组成。与带有硼酸的酰基供体配合，我们的催化剂利用局部摩尔浓度效应来促进酰基转移到目标赖氨酸残基。我们的催化剂系统采用微摩尔浓度的试剂，并提供最小的脱靶蛋白反应性。至关重要的是，BAHA 对谷胱甘肽具有抗性，谷胱甘肽是一种阻碍活细胞内非生物化学的许多努力的代谢物。在人体细胞中表达的大肠杆菌二氢叶酸还原酶。我们的结果进一步确立了众所周知的硼酸-二醇络合作为真正的生物正交反应，在化学生物学和细胞内催化中的应用。
• Oxidative damage of proline residues by nitrate radicals (NO₃˙): a kinetic and product study
  作者：Joses G. Nathanael、Jonathan M. White、Annika Richter、Madison R. Nuske、Uta Wille

  DOI：10.1039/d0ob01337d

  日期：——

  indicating that NO3˙-induced oxidation of amide bonds proceeds through initial formation of a charge transfer complex. Furthermore, the rate of oxidative damage of proline and N-methyl glycine is significantly influenced by its position in a peptide. Thus, neighbouring peptide bonds, particularly in the N-direction, reduce the electron density at the tertiary amide, which slows down the rate of ET by up

  叔酰胺，例如N-酰化脯氨酸或N-甲基甘氨酸残基，与硝酸根 (NO 3 ˙) 快速反应，在乙腈中的绝对速率系数范围为 4-7 × 10 8 M -1 s -1 。主要途径通过氮处的氧化电子转移 (ET) 进行，而在这些条件下，夺氢只是次要因素。然而，酰胺的空间位阻，例如α-碳上的烷基侧链，使速率系数降低高达 75%，表明 NO 3˙ 诱导的酰胺键氧化通过电荷转移复合物的初始形成进行。此外，脯氨酸和N-甲基甘氨酸的氧化损伤率显着受其在肽中的位置的影响。因此，相邻的肽键，特别是在N方向上，会降低叔酰胺的电子密度，从而将 ET 的速率降低多达一个数量级。这些模型研究的结果表明，与单一氨基酸相比，肽中脯氨酸残基对自由基诱导的氧化损伤的敏感性应大大降低。
• Syntheses of Phosphonic Esters of Alendronate, Pamidronate and Neridronate
  作者：Erwann Guénin、Maelle Monteil、Nadia Bouchemal、Thierry Prangé、Marc Lecouvey

  DOI：10.1002/ejoc.200601067

  日期：2007.7

  Several synthetic pathways for obtaining phosphonic esters of the amino bisphosphonic acids (NBPs) pamidronate, alendronate and neridronate were investigated. The general guideline was to react N-protected amino acids activated as phthalimide esters or as acyl chlorides. Succinimide esters were found less reactive and quickly abandoned. gamma-Lactam formation arises when starting from Boc- or Cbz-protected

  研究了获得氨基双膦酸 (NBPs) pamidronate、alendronate 和 neridronate 膦酸酯的几种合成途径。一般指导原则是将 N 保护的氨基酸作为邻苯二甲酰亚胺酯或酰氯活化。发现琥珀酰亚胺酯的反应性较低并很快被废弃。当从 Boc 或 Cbz 保护的氨基酸开始时，会形成 γ-内酰胺。邻苯二甲酰亚胺 N-保护基团允许以高产率获得这三种 NBP 的烷基或芳基单酯、二酯（对称或非对称）和三酯。((c) Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2007)。